US · Healthcare · Biotechnology
EPS came in at -0.24 against a street estimate of -0.37 — a beat of 35.1%.
Analysts rate Jasper Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.
| Fund | Stake |
|---|---|
| Velan Capital Investment Management LP | 8.02% |
| Kingdon Capital Management LLC | 4.06% |
| Morgan Stanley - Brokerage Accounts | 4.01% |
| Vanguard Capital Management, LLC | 3.52% |
| Rock Springs Capital Management LP | 3.31% |
| The Carlyle Group Inc | 3.20% |
| GSA Capital Partners LLP | 1.61% |
| Millennium Management LLC | 1.46% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jasper Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.